Publication:
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.

dc.contributor.authorPascual, J
dc.contributor.authorAttard, G
dc.contributor.authorBidard, F-C
dc.contributor.authorCurigliano, G
dc.contributor.authorDe Mattos-Arruda, L
dc.contributor.authorDiehn, M
dc.contributor.authorItaliano, A
dc.contributor.authorLindberg, J
dc.contributor.authorMerker, J D
dc.contributor.authorMontagut, C
dc.contributor.authorNormanno, N
dc.contributor.authorPantel, K
dc.contributor.authorPentheroudakis, G
dc.contributor.authorPopat, S
dc.contributor.authorReis-Filho, J S
dc.contributor.authorTie, J
dc.contributor.authorSeoane, J
dc.contributor.authorTarazona, N
dc.contributor.authorYoshino, T
dc.contributor.authorTurner, N C
dc.date.accessioned2023-05-03T14:40:50Z
dc.date.available2023-05-03T14:40:50Z
dc.date.issued2022-07-06
dc.description.abstractCirculating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a strong evidence base for use in patients with cancer. The European Society for Medical Oncology convened an expert working group to review the analytical and clinical validity and utility of ctDNA assays. For patients with advanced cancer, validated and adequately sensitive ctDNA assays have utility in identifying actionable mutations to direct targeted therapy, and may be used in routine clinical practice, provided the limitations of the assays are taken into account. Tissue-based testing remains the preferred test for many cancer patients, due to limitations of ctDNA assays detecting fusion events and copy number changes, although ctDNA assays may be routinely used when faster results will be clinically important, or when tissue biopsies are not possible or inappropriate. Reflex tumour testing should be considered following a non-informative ctDNA result, due to false-negative results with ctDNA testing. In patients treated for early-stage cancers, detection of molecular residual disease or molecular relapse, has high evidence of clinical validity in anticipating future relapse in many cancers. Molecular residual disease/molecular relapse detection cannot be recommended in routine clinical practice, as currently there is no evidence for clinical utility in directing treatment. Additional potential applications of ctDNA assays, under research development and not recommended for routine practice, include identifying patients not responding to therapy with early dynamic changes in ctDNA levels, monitoring therapy for the development of resistance mutations before clinical progression, and in screening asymptomatic people for cancer. Recommendations for reporting of results, future development of ctDNA assays and future clinical research are made.
dc.identifier.doi10.1016/j.annonc.2022.05.520
dc.identifier.essn1569-8041
dc.identifier.pmid35809752
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753422017215/pdf
dc.identifier.urihttp://hdl.handle.net/10668/21915
dc.issue.number8
dc.journal.titleAnnals of oncology : official journal of the European Society for Medical Oncology
dc.journal.titleabbreviationAnn Oncol
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.page.number750-768
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectcirculating tumour DNA (ctDNA)
dc.subjectliquid biopsy
dc.subjectprecision medicine
dc.subject.meshBiomarkers, Tumor
dc.subject.meshCirculating Tumor DNA
dc.subject.meshHumans
dc.subject.meshMutation
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshPrecision Medicine
dc.titleESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number33
dspace.entity.typePublication

Files